Latest ACR News
-
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis patients with chronic kidney disease, shows the 3 year survival to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy.Read Article
Philip Robinson philipcrobinson
5 years 1 month ago
Use of complementary and alternative medicines in #psoriatic arthritis Abs 2462 #ACR19 @RheumNow https://t.co/h8UTbOwWrJ
Dr. Dao talks with Dr. Gwenesta Melton about Women in Rheumatology
Dr. Dao interviews Dr. Melton about Women in Rheumatology
Social Media Professionalism: Dr. Michael Putman and Dr. Jilaine Bolek Berquist
Dr. Michael Putman talks with Dr. Jilaine Bolek Berquist about her talk on tweets and trolls in social media at the 2019 ACR/ARP annual meeting in Atlanta.
Domain Strategy and Treatment in Psoriatic Arthritis: Dr. Elaine Husni
Dr. Elaine Husni reviews her talk on domain strategies in PsA at the 2019 ACR/ARP annual meeting in Atlanta.
Depression in Psoriatic Arthritis: Dr. Olga Petryna
Dr. Petryna discusses the association between depression and rheumatologic conditions, including psoriatic arthritis, highlighting abstracts #178, #580, #1490 and more.
Cryoglobulinaemic Vasculitis Related to Hepatitis C: Dr. David Liew
Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: What's New in iRAEs
Drs. Laura Cappelli, Len Calabrese and Cassandra Calabrese discuss iRAE studies presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr Irwin Lim _connectedcare
5 years 1 month ago
How the immersive, perception changing VR seems to change pain experience
#ACR19 @rheumnow 5T027 https://t.co/3VBFSxrbMj
Maeve Gamble MaeveGamble
5 years 1 month ago
PEARL: The first manifestation of AAV is often a migratory oligoarthritis. Favours lower extremities. Quickly forgotten by pts. Can often herald a flare. #ACR19 @RheumNow
k dao KDAO2011
5 years 1 month ago
#acr19 @RheumNow
Love this quote by Dr J Stone:”The history is the rheumatologist’s scalpel”
Dr. John Cush RheumNow
5 years 1 month ago
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.
Cassandra Calabrese CCalabreseDO
5 years 1 month ago
Mind-blowing - patients with inflammatory joint pain as IrAE with non-inflammatory synovial fluid! What is up!? Abstr#2147 @RheumNow @LCalabreseDO @cappelliMD #ACR19 @FunchainMD @CleClinicMD https://t.co/fBg8ljMWdz
k dao KDAO2011
5 years 1 month ago
#acr19 @RheumNow
Vasculitis myths/pearls by Dr J Stone:
- steroids can fail 60% pts (side effects/not work) w/GCA in first 24 wks (use TCZ early!)
- GPA pts who still have some dz activity, add some CYP
-AAV can flare even when B cells are not measurable (B cells are there!)
Cassandra Calabrese CCalabreseDO
5 years 1 month ago
More data to support use of checkpoint inhibitor therapy in patients with pre-existing AID! No increase in frequency of irAEs abstr#2146 #ACR19 @RheumNow @cappelliMD https://t.co/Za2hZsDAgh
Olga Petryna DrPetryna
5 years 1 month ago
#ACR19 @rheumnow ABS2439 retrospective cohort study of PSA +HUC/gout shows HUC independently associated w/CVD, mainly w/ Afib (17.8% vs 6.1%, p < 0.001)& HFpEF (7.2% vs 3.1%, p < 0.001) in pts w/PsA. No statist diff in CAD btw the 2 groups (POR 1.21; 95%-CI 0.94-1.55; p=0.131) https://t.co/fZO5pjhdAZ
